The burden and clinical trajectory of immune checkpoint inhibitor-induced endocrinopathies: an 8-year experience

The burden and clinical trajectory of immune checkpoint inhibitor-induced endocrinopathies: an 8-year experience

Abstract Background Immune checkpoint inhibitors (ICIs) have revolutionized the management of cancer patients, but the emergence of ICI-related endocrinopathies (IREs) has introduced new clinical challenges. Despite worldwide recognition of these adverse effects, data from the Middle East is scarce....

Full description

Saved in:
Bibliographic Details
Main Authors: Fateen Ata, Adeel Ahmad Khan, Emad Algorani, Amr Faisal Musaed Alsharafi, Reham Abo Shdid, Mohammad Nofal, Ayman R. Ibrahim, Loai Abdullah, Khalil Youssef El Annan, Tareq Emad Hawash Al-Bkoor, Kakil Ibrahim Rasul, Tarik Elhadd, Haval Surchi
Format: Article
Language:English
Published: BMC 2024-12-01
Series:BMC Medicine
Subjects:
Immune checkpoint inhibitors
Pembrolizumab
Nivolumab
Atezolizumab
Ipilimumab
Durvalumab
Online Access:https://doi.org/10.1186/s12916-024-03812-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12916-024-03812-2

Similar Items